Most people have experienced nausea and vomiting at some point in their lives. Motion sickness can cause nausea. The good news, however, is that industrial hemp-derived cannabinoids have the potential to treat nausea. Full spectrum cannabidiol (CBD) also has some positive effects when fighting other symptoms associated with motion sickness.
What Is Motion Sickness?
Anyone who has experienced motion sickness knows how uncomfortable it can make a person. Though it has no lasting complications, it can make a person miserable if it occurs too frequently.
Motion sickness is also known as air-sickness, sea-sickness, or carsickness.
Who Is at Risk?
Anyone who travels or undergoes enough motion is at risk. The risk is higher in pregnant women and children. For those who travel frequently on boats, seasickness is also a type of motion sickness. Other factors that constitute a risk include:
- Mode of travel
- Fear and anxiety about traveling
- Poor ventilation inside the vehicle
- Inability to see through the window to help with orientation
Three Categories of Motion Sickness:
- Motion sickness due to motion that cannot be seen
- Motion sickness due to seeing something that cannot be felt
- Motion sickness due to auditory and visual symptoms detecting motion, but that do not correspond
Symptoms Associated with Motions Sickness Include:
- Nausea and vomiting
- Shortness of breath
Using Cannabinoids to Treat Motion Sickness
It is a paradox that the biological causes of nausea and vomiting help with the development of various species. It is a defense mechanism designed to act as a barrier against the digestion of toxic chemicals. Studies have shown that cannabinoid receptors play a vital role in the regulation of vomiting and nausea.
According to research, CBD activates 5-HT1A, or 5-hydroxytryptamine. This is a unique compound that reduces the sensation of nausea and the accompanying reflex of vomiting. Studies conducted on chemotherapy patients have found that cannabinoids significantly reduce vomiting and nausea. CBD supports high levels of anandamide by inhibiting the enzymes that degrade it. The inhibitory effects of CBD against nausea are credited to the prolonged activation of the CB1 receptor in the brain.
What Does the Research Say?
A German study conducted in 2010 asked participants to partake in an experiment – where the weightlessness of space travel was simulated. Blood samples were taken by the scientists before, during, and after the simulation. It was discovered that participants who had the lowest levels of cannabinoids in their system experienced the worst motion sickness.
A Chinese study conducted in 2014 proved that the drug dexamethasone reduced symptoms of motion sickness by enhancing the endocannabinoid system (ECS). As a plus, this study showed the link between the ECS and motion sickness.
The ECS regulates the interaction between the mind and the body. It affects the nervous system, organ function, and even the immune system. It works to maintain homeostasis, a term which describes the state of balance of the internal environment.
It is evident that industrial hemp-derived cannabinoids have many effective uses in treating a wide range of diseases, disorders, and conditions. No other medicine encompasses such an extensive scope of healing and treatment properties. This is because phytocannabinoids work with our natural ECS to bring us back into balance on many levels. When our immune system is overreacting, when our nervous system is out of whack, when our natural endocannabinoids are deficient, phytocannabinoids have the ability to act in their place. They are natural, safe, and effective.
But just like anything we might ingest, it is important to understand how certain of the 113 known cannabinoids can react with particular conditions and in what doses. The federal government has already made hemp-derived cannabinoids legal. It is time that science is allowed to catch up with what we already know. It is time for the government to generously fund the rigorous research of cannabinoids. Researchers are ready. Patients are ready. Let’s do everything in our power to give them access to the best treatment available.
- Turner M, Griffin MJ. Motion sickness in public road transport: passenger behavior and susceptibility. Ergonomics. 1999; 42:444–461. [PubMed]
- Turner M, Griffin MJ, Holland I. Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med. 2000; 71:1181–1189. [PubMed]
- Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med. 1988; 59:399–406. [PubMed]
- Reason JT. Motion sickness adaptation: a neural mismatch model. J Rsoc Med. 1978; 71:819–829. [PMC free article] [PubMed]
- Oman CM. Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol. 1990; 68:294–303. [PubMed]
- Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med. 2006; 77:1213–1223. [PubMed]
- Reavley CM, Golding JF, Cherkas LF, Spector TD, MacGregor AJ. Genetic influences on motion sickness susceptibility in adult women: a classical twin study. Aviat Space Environ Med. 2006; 77:1148–1152. [PubMed]
- Finley JC, Jr, O’Leary M, Wester D, MacKenzie S, Shepard N, et al. A genetic polymorphism of the alpha2-adrenergic receptor increases autonomic responses to stress. J Appl Physiol. 2004; 96:2231–2239. [PubMed]
- Otto B, Riepl RL, Klosterhalfen S, Enck P. Endocrine correlates of acute nausea and vomiting. Auton Neurosci. 2006; 129:17–21. [PubMed]
- Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol. 2007; 7:575–582. [PubMed]
- De Petrocellis L, Di Marzo V. An introduction to the endocannabinoid system: from the early to the latest concepts. Best Pract Res Clin Endocrinol Metab. 2009; 23:1–15. [PubMed]
- Di Marzo V, Melck D, Bisogno T, De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998; 21:521–528. [PubMed]
- Parker LA, Limebeer CL, Rock EM, Litt DL, Kwiatkowska M, et al. The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav. 2009; 97:121–124. [PMC free article] [PubMed]
- Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology. 2001; 121:767–774. [PubMed]
- Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA. Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol. 2003; 285:G566–G576. [PubMed]